Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide Extension in Cushing's Disease
NCT00171951Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Jul 2013
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in Cushing's disease (CD), sponsored by Novartis. Primary endpoints: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits at Month 6 and Change From Baseline in Mean Urinary Free Cortisol (UFC) at Month 102. Started Aug 2004; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT00171951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171951.